Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Buy" by Brokerages

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has earned an average recommendation of "Buy" from the eight brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $13.71.

Several equities analysts have commented on the stock. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Humacyte in a research report on Wednesday, March 12th. Benchmark reiterated a "buy" rating on shares of Humacyte in a report on Thursday, February 27th. Finally, D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of Humacyte in a report on Wednesday, March 26th.

Humacyte Stock Performance

Shares of NASDAQ HUMA traded up $0.01 during trading on Friday, reaching $1.50. The stock had a trading volume of 1,404,833 shares, compared to its average volume of 3,241,578. The business's 50-day moving average price is $3.50 and its 200-day moving average price is $4.44. Humacyte has a fifty-two week low of $1.31 and a fifty-two week high of $9.97. The company has a market cap of $188.16 million, a P/E ratio of -1.12 and a beta of 1.36.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.07. The business had revenue of $7.23 million for the quarter, compared to analysts' expectations of $0.64 million. Analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp grew its holdings in Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock valued at $25,917,000 after buying an additional 1,895,529 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Humacyte during the third quarter worth approximately $596,000. Thrivent Financial for Lutherans purchased a new position in Humacyte during the third quarter worth approximately $712,000. Barclays PLC boosted its holdings in shares of Humacyte by 177.6% in the 3rd quarter. Barclays PLC now owns 236,742 shares of the company's stock valued at $1,288,000 after purchasing an additional 151,458 shares during the last quarter. Finally, Brookstone Capital Management acquired a new stake in shares of Humacyte during the 4th quarter worth $56,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.